Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
61.74
+1.74 (2.90%)
At close: Feb 27, 2026, 4:00 PM EST
62.67
+0.93 (1.51%)
After-hours: Feb 27, 2026, 5:30 PM EST
Vaxcyte Employees
Vaxcyte had 507 employees as of December 31, 2025. The number of employees increased by 93 or 22.46% compared to the previous year.
Employees
507
Change (1Y)
93
Growth (1Y)
22.46%
Revenue / Employee
n/a
Profits / Employee
-$1,512,087
Market Cap
8.89B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 507 | 93 | 22.46% |
| Dec 31, 2024 | 414 | 160 | 62.99% |
| Dec 31, 2023 | 254 | 96 | 60.76% |
| Dec 31, 2022 | 158 | 69 | 77.53% |
| Dec 31, 2021 | 89 | 31 | 53.45% |
| Dec 31, 2020 | 58 | 15 | 34.88% |
| Dec 31, 2019 | 43 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 925 |
| Madrigal Pharmaceuticals | 915 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 673 |
| Cytokinetics | 498 |
| Halozyme Therapeutics | 423 |
| Krystal Biotech | 295 |
PCVX News
- 4 days ago - Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 17 days ago - Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines - GlobeNewsWire
- 18 days ago - Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - GlobeNewsWire
- 23 days ago - Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit - GlobeNewsWire
- 26 days ago - Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 4 weeks ago - Vaxcyte Announces Pricing of $550 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance - Seeking Alpha